Senate Bill Would Expand Medicare Obesity Coverage to More Providers, Add Weight-Loss Drug Benefits
Treat and Reduce Obesity Act of 2025
Stalled
No legislative action in over 90 days.
Legislative Progress
Key Points
Impact Analysis
Personal Impact
How this policy affects specific groups of people
Milestones
What Happens Next
Projected impacts based on AI analysis
Related News
3 articlesWill Medicare and Medicaid Cover Obesity Drugs?
Lawmakers have introduced the Treat and Reduce Obesity Act of 2025 to mandate Medicare coverage for FDA-approved obesity medications and visits with specialists. The bill would allow a variety of practitioners, including registered dietitians, to provide intensive behavioral therapy.
Medicare to Cover Blockbuster Obesity Drugs
President Trump announced a deal to expand Medicare coverage for semaglutide and tirzepatide for weight management. While the administration is using pilot programs, the Treat and Reduce Obesity Act remains the legislative path to permanently codify these benefits and expand counseling access.
Medicare to Cover Obesity Drugs Under Trump Deal for as Little as $50. What You Need to Know
A landmark deal with pharmaceutical companies will expand Medicare coverage for weight-loss medications starting in mid-2026. This move aligns with goals of the Treat and Reduce Obesity Act, which seeks to modernize Medicare by removing outdated barriers to comprehensive obesity care.
Related Bills
1 billSource Information
Analysis generated by AI. Always verify with official sources.